Relevance of frequent μ-opioid receptor polymorphisms for opioid activity in healthy volunteers

Pharmacogenomics Journal

Volumn 6, Issue 3, 2006, Pages 200-210

  Lotsch J ^a   Geisslinger, G ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Morphine; Morphine 6 glucuronide; Pharmacogenetics; PK PD modeling

Indexed keywords

ADENINE; CYSTEINE; GUANINE; MORPHINE; MORPHINE 6 GLUCURONIDE; MU OPIATE RECEPTOR; OPIATE; OPIATE RECEPTOR;

ANALGESIA; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INTRON; MALE; MIOSIS; NORMAL HUMAN; PRIORITY JOURNAL; PROCESS MODEL; PUPIL; SINGLE NUCLEOTIDE POLYMORPHISM; SUBSTANCE ABUSE; VOLUNTEER;

ALLELES; EXONS; FEMALE; GENE FREQUENCY; HUMANS; MALE; MUTATION; NARCOTICS; POLYMORPHISM, GENETIC; RECEPTORS, OPIOID, MU; REFERENCE VALUES;

EID: 33744749555     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500362     Document Type: Article

References (38)

1. Wang JB, Johnson PS, Persico AM, Hawkins AL, Griffin CA, Uhl GR. Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett 1994; 338: 217-222.
2. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996; 383: 819-823.
3. Skarke C, Darimont J, Schmidt H, Geisslinger G, Lötsch J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 2003; 73: 107-121.
4. Lötsch J, Skarke C, Grösch S, Darimont J, Schmidt H, Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the clinical activity of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 2002; 12: 3-9.
5. Romberg R, Olofsen E, Sarton E, den Hartigh J, Taschner PE, Dahan A. Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: Absence of sex differences. Anesthesiology 2004; 100: 120-133.
6. Romberg RR, Olofsen E, Bijl H, Taschner PE, Teppema LJ, Sarton EY et al. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 2005; 102: 522-530.
7. Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC et al. The 118A>G polymorphism in the human micro-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004; 48: 1232-1239.
8. Caraco Y, Maroz Y, Davidson E. Variability in alfentanil analgesia maybe attributed to polymorphism in the mu-opiod receptor gene. Clin Pharmacol Ther 2001; 69: P63.
9. Lötsch J, Zimmermann M, Darimont J, Marx C, Dudziak R, Skarke C et al. Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology 2002; 97: 814-819.
10. Hirota T, Ieiri I, Takane H, Sano H, Kawamoto K, Aono H et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos 2003; 31: 677-680.
11. Hoehe MR, Kopke K, Wendel B, Rohde K, Flachmeier C, Kidd KK et al. Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet 2000; 9: 2895-2908.
12. Skarke C, Jarrar M, Erb K, Schmidt H, Geisslinger G, Lötsch J. Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clin Pharmacol Ther 2003; 74: 303-311.
13. Skarke C, Langer M, Jarrar M, Schmidt H, Geisslinger G, Lötsch J. Probenecid interacts with the pharmacokinetics of morphine-6-glucuronide in humans. Anesthesiology 2004; 101: 1394-1399.
14. Lötsch J, Geisslinger G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 2005; 11: 82-89.
15. LaForge KS, Yuferov V, Kreek MJ. Opioid receptor and peptide gene polymorphisms: Potential implications for addictions. Eur J Pharmacol 2000; 410: 249-268.
16. Skarke C, Kirchhof A, Geisslinger G, Lötsch J. Comprehensive mu-opioid-receptor genotyping by pyrosequencing. Clin Chem 2004; 50: 640-644.
17. Niu T, Qin ZS, Xu X, Liu JS. Bayesian haplotype inference for multiple linked single-nucleotide polymorphisms. Am J Hum Genet 2002; 70: 157-169.
18. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192-209.
19. Unadkat JD, Bartha F, Sheiner LB. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models. Clin Pharmacol Ther 1986; 40: 86-93.
20. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358-371.
21. Hull CJ, Van Beem HB, McLeod K, Sibbald A, Watson MJ. A pharmacodynamic model for pancuronium. Br J Anaesth 1978; 50: 1113-1123.
22. Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981; 6: 429-453.
23. Boeckmann AJ, Sheiner LB, Beal SL. NONMEM User's Guide. University of California San Francisco: San Francisco, 1994.
24. Penson RT, Joel SP, Clark S, Gloyne A, Slevin ML. Limited phase I study of morphine-3-glucuronide. J Pharm Sci 2001; 90: 1810-1816.
25. Penson RT, Joel SP, Bakhshi K, Clark SJ, Langford RM, Slevin ML. Randomized placebo controlled trial of the activity of the morphine glucuronides. Clin Pharmacol Ther 2000; 68: 667-676.
26. Wand GS, McCaul M, Yang X, Reynolds J, Gotjen D, Lee S et al. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 2002; 26: 106-114.
27. Hernandez-Avila CA, Wand G, Luo X, Gelernter J, Kranzler HR. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet 2003; 118B: 60-65.
28. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: Possible implications for opiate addiction. Proc Natl Acad Sci USA 1998; 95: 9608-9613.
29. Beyer A, Koch T, Schroder H, Schulz S, Höllt V. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 2004; 89: 553-560.
30. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL. A single-nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 2001; 276: 3130-3137.
31. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 2005; 280: 32618-32624 (Epub 2005 July 26).
32. LaForge KS, Shick V, Spangler R, Proudnikov D, Yuferov V, Lysov Y et al. Detection of single nucleotide polymorphisms of the human mu opioid receptor gene by hybridization or single nucleotide extension on custom oligonucleotide gelpad microchips: Potential in studies of addiction. Am J Med Genet 2000; 96: 604-615.
33. Berrettini WH, Hoehe MR, Ferraro TN, Demaria PA, Gottheil E. Human mu opioid receptor gene polymorphisms and vulnerability to substance abuse. Addict Biol 1997; 2: 303-308.
34. Urraca N, Camarena B, Gomez-Caudillo L, Esmer MC, Nicolini H. micro opioid receptor gene as a candidate for the study of obsessive compulsive disorder with and without tics. Am J Med Genet 2004; 127B: 94-96.
35. Gelernter J, Kranzler H, Cubells J. Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: Population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol Psychiatr 1999; 4: 476-483.
36. Ette EI, Williams PJ. Population pharmacokinetics II: Estimation methods. Ann Pharmacother 2004; 38: 1907-1915.
37. Luo X, Kranzler HR, Zhao H, Gelernter J. Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. Am J Med Genet 2003; 120B: 97-108.
38. Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila M et al. Mu opioid receptor gene variants: Lack of association with alcohol dependence. Mol Psychiatr 1997; 2: 490-494.